Human protein C concentrate in pediatric septic patients

Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. Unlike what is
suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children. Long
before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C
zymogen. Therefore, we conducted a systemic review of currently available data on protein C zymogen (PC) use among
children affected by severe sepsis or septic shock.
A total number of 13 case series or case reports and a dose-finding study were found on the use of PC in the pediatric
intensive care unit, reporting on 118 treated children, with an overall survival of 84%. There was no bleeding complication,
the only reported complication being a single mild allergic reaction.
These studies show that PC is safe, not associated with bleeding and possibly useful for improving coagulation abnormalities
of sepsis.